A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 28, 2019

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Colorectal Cancer
Interventions
DRUG

Nivolumab

60 Minute IV Infusion

Trial Locations (14)

Unknown

Belfast City Hospital, Belfast

Queen Elizabeth Hospital, Birmingham

Velindre Cancer Centre, Cardiff

Western General Hospital, Edinburgh

Clatterbridge Cancer Centre, Liverpool

Guys Hospital, London

The Royal Marsden NHS Foundation Trust, London

University College Hospital, London

The Christie Hospital, The Christie NHS Foundation Trust, Manchester

Freemans Hospital, Newcastle upon Tyne

LS9 7TF

St James Leeds, Leeds

LE1 5WW

Leicester Royal Infirmary, Leicester

NW3 2QG

The Royal Free Hospital, London

S10 2SJ

Weston Park, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Birmingham

OTHER